Therapeutic Antibodies - from Past to Future - sprookjes - yvandenbroek - TriplyDB

Therapeutic Antibodies - from Past to Future

Therapeutic Antibodies - from Past to Future

http://www.wikidata.org/entity/Q58008023

about

Therapeutic Antibodies - from Past to Future

http://www.wikidata.org/entity/Q58008023

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2014

@uk

name

Therapeutic Antibodies - from Past to Future

@en

Therapeutic Antibodies - from Past to Future

@nl

type

label

Therapeutic Antibodies - from Past to Future

@en

Therapeutic Antibodies - from Past to Future

@nl

prefLabel

Therapeutic Antibodies - from Past to Future

@en

Therapeutic Antibodies - from Past to Future

@nl

P1476

Q58008023-6057BCBB-4DBA-4403-B79F-E27E23E34322

P2093

Q58008023-B5F1920D-CC41-4A38-AC6C-4EEDF0D463AE

P2860

Q58008023-0E85BF09-2964-4840-B1FC-DC2AFAD62BCA

Q58008023-25AA60E4-66FA-4A1C-AA45-B185F0BB1FAA

Q58008023-271985F6-B768-4956-A899-DA138DBF0EF6

Q58008023-548EE9E0-632F-4B21-B821-FA04F1B224BF

Q58008023-5A268EFD-F555-490A-9843-BC32928676F0

Q58008023-690424B7-84DB-403B-A9D7-AADB71822D31

Q58008023-8B01AD96-91A2-42B2-ABE9-14A709E8827F

Q58008023-8D8D9B98-83BA-472B-9241-B594EA081228

Q58008023-C60F4469-346D-4992-9A38-98C16BCF2E62

Q58008023-CD85674C-40E5-426D-ADAB-DB43B7F35549

P304

Q58008023-F4B8D80D-C326-44A1-B2F5-490136CC851F

P31

Q58008023-ECD83BC3-93C4-4E5B-9D7B-C97CE7E3613F

P356

Q58008023-F2F32117-4C65-4203-9614-DE2222E57A00

P50

Q58008023-68A799C6-3301-4234-A137-7576270711C0

P577

Q58008023-56B29C63-EAB2-4752-8021-F2301DC7F2F6

P356

9783527682423.CH1

P1476

Therapeutic Antibodies - from Past to Future

@en

P2093

Janice M. Reichert

http://www.w3.org/2001/XMLSchema#string

P2860

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

Generating recombinant antibodies to the complete human proteome.

Beyond natural antibodies: the power of in vitro display technologies.

Monoclonal antibodies in the clinic.

Therapeutic antibodies and antibody fusion proteins.

Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action.

Isotype and glycoform selection for antibody therapeutics.

Marketing approval of mogamulizumab: a triumph for glyco-engineering.

Antibodies to watch in 2013: Mid-year update.

Which are the antibodies to watch in 2013?

P304

1-14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/9783527682423.CH1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime